Seer Appoints Rachel Haurwitz, Ph.D., to its Board of Directors
November 08 2021 - 4:05PM
Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing
a disruptive new platform for proteomics, today announced it has
appointed Rachel Haurwitz, Ph.D. to serve on its Board of
Directors, effective November 8, 2021. Dr. Haurwitz is currently
CEO of Caribou Biosciences, Inc. a clinical-stage biopharmaceutical
company developing genome-edited off-the-shelf immune cell
therapies for the treatment of cancer. Concurrent with this
appointment, David Singer will step down from the Board of
Directors.
“We’re delighted to welcome Rachel to our Board of Directors.
Rachel is a highly accomplished and distinguished scientist and CEO
in the high-growth, emerging area of gene editing,” said Omid
Farokhzad, M.D., Chair, Chief Executive Officer and Founder of
Seer. “Rachel’s passion for our work at Seer, coupled with her
expertise, will contribute to our growth and the delivery of our
promise of opening up a new gateway to the proteome. I would like
to thank David for the invaluable role he has played to help
position Seer as a leader in proteomics, as well as his guidance
during our transition from a private to public company.”
“I am excited to join the Seer Board and eager to contribute to
the company’s inspiring mission,” said Dr. Haurwitz.
“As Seer’s technology redefines what’s possible in proteomics,
I look forward to partnering with their talented leadership team to
deliver on this remarkable promise of opening up new insights in
biology to transform human health.”
Rachel Haurwitz is a co-founder of Caribou Biosciences, Inc. and
has been its President and Chief Executive Officer and a director
since the company’s inception in 2011. Rachel is an inventor on
patents and patent applications covering multiple CRISPR-based
technologies and has co-authored several scientific papers in
high-impact journals characterizing CRISPR-Cas systems. In 2018,
the Association for Women in Science recognized Rachel with the
annual Next Generation Award. She serves on the board of directors
of the Biotechnology Organization (BIO). Rachel earned an A.B. in
Biological Sciences from Harvard College and a Ph.D. in Molecular
and Cell Biology from the University of California, Berkeley.
About Seer Inc.
Seer™ is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer is
commercializing its Proteograph™ Product Suite, an integrated
solution that includes proprietary engineered nanoparticles,
consumables, automation instrumentation and software to perform
deep, unbiased proteomic analysis at scale in a matter of hours.
Seer designed the Proteograph workflow to be efficient and easy to
use, leveraging widely adopted laboratory instrumentation to
provide a decentralized solution that can be incorporated by nearly
any lab. Seer’s Proteograph Product Suite is for research use only
and is not intended for diagnostic procedures. For more
information, please visit www.seer.bio.
Investor ContactCarrie
Mendivilinvestor@seer.bio
Media ContactKaren
Possematopr@seer.bio
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b652d7c4-3120-4d8d-ae4a-3f1b5cb7fe2d
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024